MPI-0485520 could be a very valuable compound in the MYRX portfolio. Licensing discussions seems to be very advanced. Lupus sems to be a potential first indication from a prospective partner. Still almost 5 dollar/share in pure cash and no debts.
Management looking forward to update Azixa phII at ASCO. MPI-0485520 data coming in in late May.
How do you know that "few were employees in the first place"? The titles of those two posters mention only Myrexis in Salt Lake City. My guess is that ALL the authors of those posters were (maybe some still are) MYRX employees.
Thanks, I'm invested in CLDX as well. It seems like only a handful of small companies are going after this indication. Not sure why Pfizer ended their deal, but could be worth the risk, imo.
Remember the conference call where Hobden said the other officer could not be on the call because he was in a active discussion with a potential partner? How come all these active discussions lead nowhere? Lack of faith in the "experienced management" perhaps? Kind of like active herpes, where it leads nowhere and comes back when the new partner is about to close the deal
This is an unusually tricky negotiation. The drug is a better-than-expected candidate against rheumatoid arthritis. Lupus might be a $1 Bln market; RA is at least 20x as large. It's bad enough trying to satisfy everyone when you're doing an exclusive license for a single candidate that might do $a couple hundred MM a year of business. Here, the license covers a family of candidates, they may be licensed to multiple partners for different indications, and the market size can't be realistically estimated. And we don't even know for sure that effective drug levels are achievable in humans. I don't expect early action.